Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer.
Keyword(s):
Phase Ii
◽
2016 ◽
Vol 158
(1)
◽
pp. 91-97
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 607-607